Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…ed, which was considered unrelated to the treatment.Conclusions Vactosertib demonstrated a manageable safety profile and an encouraging ant…
…mors to 3 separate cohorts: tissue-agnostic TMB-H or MSI-H, and colorectal cancer. All patients receive recommended Phase 2 dose of 0.08 mg/kg i.…
…h all patient biopsies, achieving the primary endpoint. Ex-vivo pembrolizumab response rate was 14% (2 of 14 samples evaluated thus far), whi…
…d with METex14 subtypes was used to impute subtypes in a second NSCLC cohort with immunotherapy outcomes (N=205).Results METex14 tumo…
… 30% variation across strata, and a 60% hazard reduction due to aspirin, the required sample size to achieve 80% power is 760 patients.…
…Background Cold solid tumors, including pancreatic, prostate, and microsatellite stable colo…
… which can be leveraged therapeutically. These findings support SyntiGen as a promising strategy for personalized and localized cancer i…
…l and continuous immune engager production for the treatment of prostate cancer.Abstract 1032 Figure 1Transduced NK cells continue to express G…
…stic causes. In patients with signs and symptoms suggestive for myositis, a diagnostic muscular biopsy was performed.Results From Januar…
…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…
…anuary 2003 to September 2022, 453 patients were diagnosed with malignant melanoma and were treated with immunotherapy or targeted therapy. The me…
…8.9% were male and 51.1% were female. The most common ICIs were Pembrolizumab (16276, 45.38%), Nivolumab (10548, 29.41%), Ipilimumab (3120, 8…